- Home
- IMNM vs COLL Comparison
IMNM vs COLL Comparison
Compare IMNM & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- COLL
- Stock Information
- Founded
- IMNM 2006
- COLL 2002
- Country
- IMNM United States
- COLL United States
- Employees
- IMNM N/A
- COLL N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- COLL Health Care
- Exchange
- IMNM Nasdaq
- COLL Nasdaq
- Market Cap
- IMNM 987.1M
- COLL 958.8M
- IPO Year
- IMNM 2020
- COLL 2015
- Fundamental
- Price
- IMNM $13.83
- COLL $33.37
- Analyst Decision
- IMNM Strong Buy
- COLL Strong Buy
- Analyst Count
- IMNM 9
- COLL 4
- Target Price
- IMNM $24.89
- COLL $44.25
- AVG Volume (30 Days)
- IMNM 2.0M
- COLL 401.3K
- Earning Date
- IMNM 11-12-2025
- COLL 11-06-2025
- Dividend Yield
- IMNM N/A
- COLL N/A
- EPS Growth
- IMNM N/A
- COLL N/A
- EPS
- IMNM N/A
- COLL 1.06
- Revenue
- IMNM $12,589,000.00
- COLL $707,007,000.00
- Revenue This Year
- IMNM N/A
- COLL $22.23
- Revenue Next Year
- IMNM $154.70
- COLL $2.78
- P/E Ratio
- IMNM N/A
- COLL $31.62
- Revenue Growth
- IMNM 16.74
- COLL 22.61
- 52 Week Low
- IMNM $5.15
- COLL $23.23
- 52 Week High
- IMNM $15.13
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- IMNM 67.38
- COLL 36.46
- Support Level
- IMNM $11.25
- COLL $34.19
- Resistance Level
- IMNM $12.00
- COLL $35.83
- Average True Range (ATR)
- IMNM 1.01
- COLL 1.03
- MACD
- IMNM 0.40
- COLL -0.29
- Stochastic Oscillator
- IMNM 87.06
- COLL 6.56
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.